M&A Deal Summary

Precigen Acquires Oxitec

On August 10, 2015, Precigen acquired life science company Oxitec from Oxford Capital for 160M USD

Acquisition Highlights
  • This is Precigen’s 8th transaction in the Life Science sector.
  • This is Precigen’s largest (disclosed) transaction.
  • This is Precigen’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2015-08-10
Target Oxitec
Sector Life Science
Buyer(s) Precigen
Sellers(s) Oxford Capital
Deal Type Add-on Acquisition
Deal Value 160M USD

Target

Oxitec

Oxford, United Kingdom
website
Oxitec Ltd. is a provider of biological insect control solutions. Oxitec Ltd. was founded in 2002 and is based in Oxford, UK.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Precigen

Germantown, Maryland, United States

website

Category Company
Founded 1998
Sector Life Science
Employees423
Revenue 103M USD (2020)
DESCRIPTION

Precigen is engaged to create biologically based products and processes that improve the quality of life and health of the planet. The science underlying these products is known as synthetic biology – an engineered approach to the field of biology. Precigen was founded in 1998 and is based in Germantown, Maryland.

DEAL STATS #
Overall 8 of 10
Sector (Life Science) 8 of 9
Type (Add-on Acquisition) 6 of 7
Country (United Kingdom) 1 of 1
Year (2015) 4 of 4
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-20 Okanagan Specialty Fruits

Summerland, British Columbia, Canada

Okanagan Specialty Fruits, Inc. is a agriculture biotechnology company. It specializes in developing tree fruit varieties with novel attributes.

Buy $31M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-24 GenVec

Gaithersburg, Maryland, United States

GenVec, Inc. is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine.

Buy -

Seller(S) 1

SELLER

Oxford Capital

Investor Investor

website

Category Venture Capital Firm
Founded 1999
Size Small
Type Sector Agnostic
DESCRIPTION

Oxford Capital is a private investment management firm that looks to acquire stakes in unlisted UK-based companies. The Firm's strategies include early stage venture capital, infrastructure, and opportunities in media. Oxford Capital was formed in 1999 and is headquartered in Oxford, England.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 2 of 2
Country (United Kingdom) 2 of 2
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-08-28 Sirigen Group

Ringwood, United Kingdom

Sirigen Group Ltd. is a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies. Sirigen provides greater sensitivity and permits analysis of more markers for the investigation and management of diseases like HIV and leukaemia, providing more meaningful information about disease earlier. Sirigen Group was formed in 2003 and is based in Ringwood, United Kingdom.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-01-12 Import.io

San Antonio, Texas, United States

Import.io is a business data platform focused on enabling businesses to convert a website to a spreadsheet or an API. Import.io was founded in 2012 and is based in San Antonio, Texas.

Buy -
Mergr

Product

Company

Legal